I. Related Technical Fields
Related technical fields include cannulas and clamping methods, and more specifically, cannulas and clamping methods for perfusing one or more organs to monitor, treat, sustain and/or restore the viability of the organ(s) and/or for transporting and/or storing the organ(s).
II. Related Art
Various devices have been developed that couple the anatomy of an organ being perfused to a machine or other equipment. Such devices are typically referred to as perfusion clamps or simply cannulas. Although the term cannula in general use has other meanings, the term cannula is used generically throughout the specification to refer to a clamp or other device that provides a connection through which a fluid flow may be established.
A type of cannula as described in U.S. Pat. No. 5,728,115 to Westcott et al., which is hereby incorporated by reference, is shown in
In use, the clamp 10 is attached to the renal aorta 34 of a donor organ such as a kidney 36 by opening the clamp 10, passing the distal end 38 of the renal aorta 34 through the annular clamp head 24, holding the distal end 38 of the renal aorta 34 over the annular clamp head 24, and releasing pressure on the handles of the clamp 10 in order to allow the clamp head 26 to engage the distal end 38 of the renal aorta 34 against the annular clamp head 24. A catheter 40 may then be attached to the nipple 28 in order to provide perfusion of liquid through the lumen 32 and into the renal aorta 34
U.S. Patent Application Publication No. 2004/0111104 to Schein et al., which is hereby incorporated by reference, discloses another type of cannula.
The cannulas as described above require the use of an aortic patch also known as a Carrel patch, or cuff. An aortic patch is a section of the aorta that remains attached to the organ when the organ is removed from an organ donor. The aortic patch is used to facilitate cannulation of vasculature of the donated organ. An aortic patch is typically only available from a deceased donor because of the resultant damage to the aorta required for an aortic patch. As such, the cannulas described above suffer from a problem in that they are not suitable for use with organs, such as a kidney, donated from a living donor or organs where an aortic patch is otherwise not available. With such an organ, the amount of tissue available for cannulation is much less. Care must be taken not to damage the limited amount of tissue available when attaching a cannula so that adequate tissue remains to reconnect the organ when the organ is transplanted to the recipient, and to prevent damage that could result in loss of the organ.
Exemplary implementations of the broad inventive principles described herein provide a cannula that can be used without an aortic patch. Exemplary implementations provide a cannula with a first circumferential portion, a second circumferential portion; and a seal with a first clamping surface. The first circumferential portion and the second circumferential portion are configured to mutually cooperate to support a circumference of vasculature and form a second clamping surface. The first clamping surface and the second clamping surface are configured to cooperate to secure an end of the vasculature. These exemplary implementations provide a solution to problems and disadvantages discussed above because the exemplary implementations do not require an aortic patch and only engage a minimal amount of tissue.
Exemplary implementations of the broad inventive principles described herein provide a method of cannulating vasculature of an organ. The method includes enclosing a circumference of the vasculature with a first circumferential portion of a cannula and a second circumferential portion of the cannula to support the vasculature while maintaining a capability to flow liquid through the vasculature. The method includes contacting an end of the vasculature with a sealing portion of the cannula in a manner that maintains the capability to flow liquid through the vasculature to ensure a substantially leak free condition during perfusion. These exemplary implementations provide a solution to problems and disadvantages discussed above because the exemplary implementations do not require an aortic patch and only engage a minimal amount of tissue.
Exemplary implementations of the broad inventive principles described herein provide a cannula with an optically clear portion configured to allow a user to view at least one portion of an interior of vasculature and a seal when the cannula is in a position in which an end of the vasculature is secured by the cannula. The optically clear portion provides optical magnification of the artery in relation to its position in the cannula. These exemplary implementations provide a solution to problems and disadvantages discussed above because they allow for inspection of the vasculature for damage and proper connection while cannulated. The magnification may also allow the clinician to observe for trapped air bubbles or clots, or to observe the intima of the artery for damage. Also, these exemplary implementations require less tissue from the vasculature to be used because the tissue can be readily viewed in the cannula to confirm that the cannula is properly connected. Thus, excess tissue does not need to be used in order to confirm that the tissue is properly cannulated.
Exemplary implementations can be described with reference to the following figures wherein:
Preservation of organs by machine perfusion has been accomplished at hypothermic temperatures with or without computer control with crystalloid perfusates and without oxygenation. See, for example, U.S. Pat. Nos. 5,149,321, 5,395,314, 5,584,804, 5,709,654 and 5,752,929 and U.S. patent application Ser. No. 08/484,601 to Klatz et al., which are hereby incorporated by reference.
Ideally organs would be procured in a manner that limits their warm ischemia time to essentially zero. Unfortunately, in reality, many organs, especially from non-beating heart donors, are procured after extended warm ischemia time periods (i.e. 45 minutes or more). The machine perfusion of these organs at low temperature has demonstrated significant improvement (Transpl Int 1996 Daemen). Numerous control circuits and pumping configurations have been utilized to achieve this objective and to machine perfuse organs in general. See, for example, U.S. Pat. Nos. 5,338,662 and 5,494,822 to Sadri; U.S. Pat. No. 4,745,759 to Bauer et al.; U.S. Pat. Nos. 5,217,860 and 5,472,876 to Fahy et al.; U.S. Pat. No. 5,051,352 to Martindale et al.; U.S. Pat. No. 3,995,444 to Clark et al.; U.S. Pat. No. 4,629,686 to Gruenberg; U.S. Pat. Nos. 3,738,914 and 3,892,628 to Thome et al.; U.S. Pat. Nos. 5,285,657 and 5,476,763 to Bacchi et al.; U.S. Pat. No. 5,157,930 to McGhee et al.; and U.S. Pat. No. 5,141,847 to Sugimachi et al., which are hereby incorporated by reference.
The cannulas and clamping methods described herein may be used in conjunction with apparatus and methods described in U.S. Pat. Nos. 6,014,864, 6,183,019, 6,241,945 and 6,485,450 to Owen, which are hereby incorporated by reference. While these apparatus and methods are related to organ recovery and transplantation, the cannulas and clamping methods described herein may also be used in various other medical procedures and with various other medical equipment where clamping with fluid flow is desired. Thus, the cannulas and clamping methods described herein are not limited to the applications described below in conjunction with the exemplary implementations.
The medical fluid for perfusion may be any suitable medical fluid. For example, it may be a simple crystalloid solution, or may be augmented with an appropriate oxygen carrier. The oxygen carrier may, for example, be washed, stabilized red blood cells, cross-linked hemoglobin, pegolated hemoglobin or fluorocarbon based emulsions. The medical fluid may also contain antioxidants known to reduce peroxidation or free radical damage in the physiological environment and specific agents known to aid in tissue protection. Further, the medical fluid may also include blood or blood products.
The cannula 100 is shown in
Although the first circumferential portion 110 and the second circumferential portion 120 are shown as rotatably connected at the first hinge 150, other methods of connection are contemplated by the broad inventive principles described herein. For example, at least one of the first circumferential portion 110 and the second circumferential portion 120 could be unattached before closure, and then snap fitted to the other of the first circumferential portion 110 and the second circumferential portion 120. Alternatively, first circumferential portion 110 and the second circumferential portion 120 could translate on pins or rails. Many implementations of relative movement between these two parts are within the broad inventive principles described herein.
Both of the first circumferential portion 110 and the second circumferential portion 120 include a tapered portion 190. As shown in
After the vasculature is supported between the first circumferential portion 110 and the second circumferential portion 120, a seal 130 is brought into contact with an end of the vasculature. This can be achieved by rotating a chamber portion 160, via a second hinge 152, into a closed position (as shown in
Free flow to and from an interior of the vasculature can be achieved by a flow passage 136. The flow passage 136 may be a circular hole through the seal 130, which may also be circular. The shape of the seal 130 and flow passage 136 are not limited to being circular, and may be influenced by other design considerations.
The seal 130 may be made of an elastomeric material. This will help to prevent damage to the vasculature, particularly an interior of the vasculature, which may be more susceptible to damage than an exterior of the vasculature. The shore A hardness (also known as the durometer) of the seal 130 can be chosen to be within a range of not less than about 32 and not greater than about 70 or within any smaller range therein, such as, preferably not less than about 60 and not greater than about 65. As used herein, the term “about” is intended to account for inherent manufacturing tolerances and inaccuracy in measurement. The hardness may be further tailored within or outside of these ranges depending upon the needs of the vasculature to be cannulated. Seals 130 of various hardness and/or seals 130 with different sizes of the flow passage 136 may be included with the cannula 100 to form a kit that can be used with different vasculatures.
The seal 130 is mated with a first opening (not labeled) in a chamber 162 of the chamber portion 160. The flow passage 136 allows liquid communication from the vasculature to the chamber 162. The chamber portion 160 also includes a second opening 166 and a third opening 168 in fluid communication with the chamber. The second opening 166 and the third opening 168 provide a “lateral” fluid flow, i.e., a flow of fluid that is substantially perpendicular to the direction of fluid flow to and from the tissue to which the cannula is attached. For example, the one or more fittings of the cannula are oriented to have an axis of fluid flow that is substantially perpendicular to an axis of fluid flow into/out of the flow passage 136. This “lateral” fluid flow arrangement allows the cannula to be connected to tubing of an organ transporter, for example, that is substantially in a single plane, for example, as described in U.S. Pat. No. 7,678,563 and U.S. Patent Application Publication No. 2004/0221719, both of which are hereby incorporated by reference. Further, multiple cannulas may be connected and even interconnected within substantially the same plane.
One or both of the second opening 166 and the third opening 168 may be connected to a fitting utilized for priming and/or air bubble removal. A second fitting 107 comprises a port or valve for such purpose. The second opening 166 and the third opening 168 may be may also be used to network multiple cannulas, for example, by connecting tubing in parallel, for example, by running a split infuse line to the first fitting of each cannula, or in series, for example, by connecting the first fitting of a cannula to the second fitting of another cannula. Standard luer geometry or other suitable structure may be used for the fittings.
The chamber portion 160 may include an optically clear portion 170. The optically clear portion 170 allows for visual inspection of the interior of the cannula. This is particularly advantageous in that it allows a user to inspect the clamping of vasculature within the cannula and to inspect for other things such as damage to the vasculature or bubbles within or flowing through the cannula. The optically clear portion may provide optical magnification to allow the user to see more detail of the vasculature, which can be relatively small, perhaps three to seven millimeters in diameter.
As shown in
The serrations and/or knurls 180 may also be included on the second clamping surface 134. Preferably, there are no serrations and/or knurls on the first clamping surface 132 because the first clamping surface 132 may contact an interior of the vasculature, which is more susceptible to damage. The relatively soft elastomeric material of the seal 130 (and therefore of the second clamping surface 132) will help to prevent damage to the interior surface of the vasculature. The length of the seal that enters the intima of the artery is minimized, therefore minimizing damage to the inside of the artery.
A notch 210 may also be included in one or both of the first circumferential portion 110 and the second circumferential portion 120. Four such notches are shown in
While various features have been described in conjunction with the examples outlined above, various alternatives, modifications, variations, and/or improvements of those features and/or examples may be possible. Accordingly, the examples, as set forth above, are intended to be illustrative. Various changes may be made without departing from the broad spirit and scope of the underlying inventive principles.
Number | Name | Date | Kind |
---|---|---|---|
3406531 | Swenson et al. | Oct 1968 | A |
3538915 | Frampton et al. | Nov 1970 | A |
3545221 | Swenson et al. | Dec 1970 | A |
3607646 | de Roissart | Sep 1971 | A |
3654085 | Norr et al. | Apr 1972 | A |
3660241 | Michielsen | May 1972 | A |
3777507 | Burton et al. | Dec 1973 | A |
3810367 | Peterson | May 1974 | A |
3843455 | Bier | Oct 1974 | A |
3877843 | Fischel | Apr 1975 | A |
3881990 | Burton et al. | May 1975 | A |
3914954 | Doerig | Oct 1975 | A |
3935065 | Doerig | Jan 1976 | A |
3995444 | Clark et al. | Dec 1976 | A |
4006744 | Steer | Feb 1977 | A |
4112944 | Williams | Sep 1978 | A |
4186565 | Toledo-Pereyra | Feb 1980 | A |
4242883 | Toledo-Pereyra | Jan 1981 | A |
4462215 | Kuraoka et al. | Jul 1984 | A |
4471629 | Toledo-Pereyra | Sep 1984 | A |
4473637 | Guibert | Sep 1984 | A |
4474016 | Winchell | Oct 1984 | A |
4494385 | Kuraoka et al. | Jan 1985 | A |
4502295 | Toledo-Pereyra | Mar 1985 | A |
4723974 | Ammerman | Feb 1988 | A |
4745759 | Bauer et al. | May 1988 | A |
4766740 | Bradley et al. | Aug 1988 | A |
4800879 | Golyakhovsky et al. | Jan 1989 | A |
4837390 | Reneau | Jun 1989 | A |
4951482 | Gilbert | Aug 1990 | A |
4958506 | Guilhem et al. | Sep 1990 | A |
5004457 | Wyatt | Apr 1991 | A |
5141847 | Sugimachi et al. | Aug 1992 | A |
5157930 | McGhee et al. | Oct 1992 | A |
5217860 | Fahy et al. | Jun 1993 | A |
5285657 | Bacchi et al. | Feb 1994 | A |
5326706 | Yland et al. | Jul 1994 | A |
5356771 | O'Dell | Oct 1994 | A |
5362622 | O'Dell et al. | Nov 1994 | A |
5383854 | Safar et al. | Jan 1995 | A |
5385821 | O'Dell et al. | Jan 1995 | A |
5434045 | Jost | Jul 1995 | A |
5472876 | Fahy | Dec 1995 | A |
5496289 | Wenstrom, Jr. | Mar 1996 | A |
5586438 | Fahy | Dec 1996 | A |
5681740 | Messier et al. | Oct 1997 | A |
5723282 | Fahy et al. | Mar 1998 | A |
5728115 | Westcott et al. | Mar 1998 | A |
5814016 | Valley et al. | Sep 1998 | A |
5821045 | Fahy et al. | Oct 1998 | A |
5856081 | Fahy | Jan 1999 | A |
5965433 | Gardetto et al. | Oct 1999 | A |
6046046 | Hassanein | Apr 2000 | A |
6355010 | Barbut | Mar 2002 | B1 |
6626869 | Bint | Sep 2003 | B1 |
6726651 | Robinson et al. | Apr 2004 | B1 |
7678563 | Wright et al. | Mar 2010 | B2 |
20040111104 | Schein et al. | Jun 2004 | A1 |
20040221719 | Wright et al. | Nov 2004 | A1 |
20060247498 | Bonadio et al. | Nov 2006 | A1 |
20080086080 | Mastri et al. | Apr 2008 | A1 |
20110059429 | Owen et al. | Mar 2011 | A1 |
Number | Date | Country |
---|---|---|
38 08 942 | Sep 1989 | DE |
43 24 637 | Mar 1995 | DE |
0 096 997 | Dec 1983 | EP |
0 376 763 | Jul 1990 | EP |
2 218 407 | Aug 2010 | EP |
2-258701 | Oct 1990 | JP |
760972 | Sep 1980 | SU |
WO 9103934 | Apr 1991 | WO |
WO 9114364 | Oct 1991 | WO |
WO 9300808 | Jan 1993 | WO |
WO 9605727 | Feb 1996 | WO |
WO 9613288 | May 1996 | WO |
WO 9629865 | Oct 1996 | WO |
WO 9630111 | Oct 1996 | WO |
WO 9745527 | Dec 1997 | WO |
WO 9915011 | Apr 1999 | WO |
WO 0018226 | Apr 2000 | WO |
WO 0226034 | Apr 2002 | WO |
WO 2006105444 | Oct 2006 | WO |
WO 2008017329 | Feb 2008 | WO |
Entry |
---|
Sep. 4, 2012 International Search Report issued in Application No. PCT/US2012/033234. |
Sep. 4, 2012 Written Opinion issued in Application No. PCT/US2012/033234. |
“Organ Preservation”, J.H. Southard, Ph.D. and F.O. Belzer, M.D., Principles of Organ TransplantationChapter 10, pp. 194-215, 1989. |
“Organko Servierungsmachine OKM 82”, Von Dietmer Scholz et al., East German Article, 1983 (with English Translation). |
“Preservation of Cerebral Function During Circulatory Arrest and Resuscitation: Hypothermic Protective Considerations”, Robert J. White, Resuscitation, vol. I, pp. 107-115, 1972. |
“Storage and Transport of Heart and Heart-Lung Donor Organs With Inflatable Cushions and Eutectoid Cooling”, D.R. Wheeldon et al., The Journal of Heart Transplantation, vol. 7, pp. 265-268, 1988. |
“MOX®-100 Renal Preservation System”, Waters Instruments Medical Group, pp. 2-7, 1982. |
“Organ Perfusion Systems: An Evaluation Criteria”, Fereydoon Sadri, Ph.D., T.O.P.S. Medical Corporation, pp. 1-8, 1987. |
Gauke Kootstra et al, “A New Device Towards Intermediate Term Kidney Preservation—An Experimental Study,” 1980, pp. 86-89. |
Jul. 22, 2013 International Preliminary Report on Patentability issued in International Application No. PCT/US2012/033234. |
Number | Date | Country | |
---|---|---|---|
20120277687 A1 | Nov 2012 | US |